Dipna Pharmachem Ltd

As of November 21, 2025, Dipna Pharmachem is considered overvalued due to a high PE ratio of 41.87 and low ROE of 2.52%, despite a strong one-year stock return of 150.22%, especially when compared to peers like Sun Pharma and Cipla.

On 21-Nov, Dipna Pharmachem Ltd witnessed a significant intraday price increase of 8.9%, closing at ₹16.89, despite opening with a notable gap down. This sharp rebound reflects heightened volatility and increased investor participation, marking a notable development for the stock amid a challenging recent performance backdrop.

Dipna Pharmachem will announce its results on 26 November 2025.

Dipna Pharmachem has experienced significant financial fluctuations, with net sales dropping from 727.56 Cr in March 2022 to 124.92 Cr in March 2025, alongside negative cash flow and declining operating profit. Overall, the company faces challenges marked by revenue declines and cash flow issues.

As of 17-Nov, Dipna Pharmachem Ltd's stock price is declining at 18.23, down 4.05% and underperforming its sector. Despite strong historical returns, recent trends show a significant disconnect with the broader market, highlighted by a 14.41% decline over the past month.

Dipna Pharmachem has experienced significant fluctuations in its financial performance, with net sales peaking at 727.56 Cr in Mar'22 and declining to 124.92 Cr in Mar'25, alongside a drop in operating profit from 22.10 Cr to 3.45 Cr during the same period, indicating challenges in generating consistent revenue and cash flow.

Dipna Pharmachem is scheduled to announce its results on 14 November 2025.

As of November 10, 2025, Dipna Pharmachem is considered overvalued with a PE ratio of 49.33 and an EV to EBIT of 18.79, despite a strong one-year stock return of 172.5%, making it less attractive compared to peers like Sun Pharma and Cipla.

As of November 7, 2025, Dipna Pharmachem is considered very expensive and overvalued with a PE ratio of 49.38 and low ROE of 2.52%, significantly higher than peers like Sun Pharma and Cipla, despite a strong year-to-date return of 38.24%.

As of November 7, 2025, Dipna Pharmachem is considered very expensive and overvalued with a PE ratio of 49.38 and an EV to EBIT ratio of 18.81, especially when compared to peers like Sun Pharma and Cipla, despite a strong one-year stock return of 161.07%.

As of November 7, 2025, Dipna Pharmachem is considered very expensive with a PE ratio of 49.38 and an EV to EBITDA of 18.75, significantly overvalued compared to peers like Sun Pharma and Cipla, despite a strong annual return of 161.07% and recent volatility reflected in a 1-month return of -13.13%.

As of 31-Oct, Dipna Pharmachem Ltd's stock price is at 19.63, down 1.36% and underperforming its sector. Despite a strong year-to-date return of 36.22%, recent trends show a decline of 2.87% over the past week, indicating challenges in investor sentiment.

As of October 16, 2025, Dipna Pharmachem is considered overvalued despite a slight improvement in valuation grade, with a high PE ratio of 51.81 and low ROE of 2.52%, indicating speculative interest rather than strong fundamentals.

As of 16-Oct, Dipna Pharmachem Ltd's stock price is Rs 20.90, down 5.0%, with a significant decline in investor participation and a bearish trend despite strong long-term performance. The stock has underperformed relative to the broader market, which has seen positive gains.

As of 15-Oct, Dipna Pharmachem Ltd's stock price is declining at 22.00, down 3.47% today and 8.71% over the last two days. Despite strong long-term returns, recent trading shows decreased investor participation and weaker short-term performance compared to the benchmark Sensex.

As of October 14, 2025, Dipna Pharmachem is considered very expensive and overvalued with a PE ratio of 56.27 and a low ROE of 2.52%, significantly higher than peers like Sun Pharma and Cipla, despite a strong year-to-date return of 57.53%.

As of 13-Oct, Dipna Pharmachem Ltd's stock price is Rs 23.85, up 4.84% today, with a year-to-date increase of 65.51%. Despite strong performance and trading above major moving averages, a significant drop in investor participation raises concerns about the stock's stability.

As of 06-Oct, Dipna Pharmachem Ltd's stock price is rising to Rs 21.84, reflecting a 5.0% increase. The stock has shown strong performance with a year-to-date increase of 51.56% and significant investor interest, indicated by a 539.53% rise in delivery volume compared to the 5-day average.

As of September 23, 2025, Dipna Pharmachem is considered overvalued with a PE ratio of 50.54 and an EV to EBIT ratio of 19.58, despite a strong one-year stock return of 158.87%, especially when compared to its peers like Sun Pharma and Cipla, which have significantly lower valuation ratios.